Harpagophytum procumbens (Devil's Claw) is often used in the supportive treatment of inflammatory and degenerative diseases of the skeletal system. Here we studied the anti-inflammatory properties of the Harpagophytum extract SteiHap 69 (Steiner Harpagophytum procumbens extract 69) on primary human monocytes, a useful model of peripheral inflammation. After eliminating lipopolysaccharides of bacterial origin, SteiHap 69 prevented the LPS-induced synthesis of tumour necrosis factor alpha (TNFα) in stimulated primary human monocytes in a dose-dependent manner. Harpagide and harpagoside had no effect on LPS-induced TNFα-release. Our data provides evidence that the Harpagophytum extract SteiHap 69 has anti-inflammatory properties. Further studies are required in order to elucidate the molecular mechanism of Devil's claw anti-inflammatory effects.
Journal article
Inhibition of TNF-α synthesis in LPS-stimulated primary human monocytes by Harpagophytum extract SteiHap 69
Phytomedicine, Vol.8(1), pp.28-30
2001
Metrics
36 Record Views
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites
Abstract
Details
- Title
- Inhibition of TNF-α synthesis in LPS-stimulated primary human monocytes by Harpagophytum extract SteiHap 69
- Creators
- B L Fiebich - University of Freiburg Medical SchoolMichael Heinrich - University of LondonK O Hiller - Deutsche Arzneimittel GesellschaftN Kammerer - VivaCell Biotechnology GmbH, Germany
- Publication Details
- Phytomedicine, Vol.8(1), pp.28-30
- Identifiers
- 1448; 991012820767802368
- Academic Unit
- Southern Cross Plant Science
- Resource Type
- Journal article